Regulatory dependence and Scientific Advisory Boards
The Food and Drug Administration (FDA) uses scientific procedures to evaluate regulated firms' new product applications. Much of its basic intellectual resources, in the form of scientific advisory committee members, come from research institutions. Regulated firms may seek connections to the FDA advisory committee members to affect the regulatory approval process. However, individual linkages may fail. The use of Scientific Advisory Boards (SAB) with multiple members provides redundant ties to the regulator, which means that the failure of each tie becomes less material. This paper is principally concerned with the firm's motivation to rebalance power imbalances rather than any actual regulatory outcomes. Controlling for alternative explanations, I find that dependence on the regulator is positively associated with the probability of having a SAB. Selected network diagrams add credibility to the hypothesis.
Please report citation or reference errors to , or , if you are the registered author of the cited work, log in to your RePEc Author Service profile, click on "citations" and make appropriate adjustments.:
- Nelson, Richard R., 2004.
"The market economy, and the scientific commons,"
Elsevier, vol. 33(3), pages 455-471, April.
- Czarnitzki, Dirk & Glänzel, Wolfgang & Hussinger, Katrin, 2007.
"Heterogeneity of Patenting Activity and Its Implications for Scientific Research,"
ZEW Discussion Papers
07-028, ZEW - Zentrum für Europäische Wirtschaftsforschung / Center for European Economic Research.
- Czarnitzki, Dirk & Glänzel, Wolfgang & Hussinger, Katrin, 2009. "Heterogeneity of patenting activity and its implications for scientific research," Research Policy, Elsevier, vol. 38(1), pages 26-34, February.
- Michael Spence, 1973. "Job Market Signaling," The Quarterly Journal of Economics, Oxford University Press, vol. 87(3), pages 355-374.
- Mansfield, Edwin & Schwartz, Mark & Wagner, Samuel, 1981. "Imitation Costs and Patents: An Empirical Study," Economic Journal, Royal Economic Society, vol. 91(364), pages 907-18, December.
- Kandel, E. & Lazear, E.P., 1990.
"Peer Pressure and Partnerships,"
90-07, Rochester, Business - Managerial Economics Research Center.
- Zucker, Lynne G & Darby, Michael R & Brewer, Marilynn B, 1998. "Intellectual Human Capital and the Birth of U.S. Biotechnology Enterprises," American Economic Review, American Economic Association, vol. 88(1), pages 290-306, March.
- Liebeskind, Julia Porter, 1997. "Keeping Organizational Secrets: Protective Institutional Mechanisms and Their Costs," Industrial and Corporate Change, Oxford University Press, vol. 6(3), pages 623-63, September.
- Wesley M. Cohen & Richard R. Nelson & John P. Walsh, 2000.
"Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (or Not),"
NBER Working Papers
7552, National Bureau of Economic Research, Inc.
- Wesley M Cohen & Richard R Nelson & John P Walsh, 2003. "Protecting Their Intellectual Assets: Appropriability Conditions and Why U.S. Manufacturing Firms Patent (Or Not)," Levine's Working Paper Archive 618897000000000624, David K. Levine.
- Paul Willman & David Coen & David Currie & Martin Siner, 2003. "The evolution of regulatory relationships; regulatory institutions and firm behaviour in privatized industries," Industrial and Corporate Change, Oxford University Press, vol. 12(1), pages 69-89, February.
- Scott Shane & Daniel Cable, 2002. "Network Ties, Reputation, and the Financing of New Ventures," Management Science, INFORMS, vol. 48(3), pages 364-381, March.
- Stephan, Paula E & Everhart, Stephen S, 1998. "The Changing Rewards to Science: The Case of Biotechnology," Small Business Economics, Springer, vol. 10(2), pages 141-51, March.
- Kim, Jerry W. & Higgins, Monica C., 2007. "Where do alliances come from?: The effects of upper echelons on alliance formation," Research Policy, Elsevier, vol. 36(4), pages 499-514, May.
- Sampat, Bhaven N., 2006. "Patenting and US academic research in the 20th century: The world before and after Bayh-Dole," Research Policy, Elsevier, vol. 35(6), pages 772-789, July.
- Roijakkers, Nadine & Hagedoorn, John, 2006. "Inter-firm R&D partnering in pharmaceutical biotechnology since 1975: Trends, patterns, and networks," Research Policy, Elsevier, vol. 35(3), pages 431-446, April.
- Megginson, William L & Weiss, Kathleen A, 1991. " Venture Capitalist Certification in Initial Public Offerings," Journal of Finance, American Finance Association, vol. 46(3), pages 879-903, July.
- Louis, Karen Seashore, et al, 2001. "Entrepreneurship, Secrecy, and Productivity: A Comparison of Clinical and Non-clinical Life Sciences Faculty," The Journal of Technology Transfer, Springer, vol. 26(3), pages 233-45, June.
- Ajay Agrawal & Rebecca Henderson, 2002. "Putting Patents in Context: Exploring Knowledge Transfer from MIT," Management Science, INFORMS, vol. 48(1), pages 44-60, January.
- Lynne G. Zucker & Michael R. Darby & Jeff S. Armstrong, 2002.
"Commercializing Knowledge: University Science, Knowledge Capture, and Firm Performance in Biotechnology,"
INFORMS, vol. 48(1), pages 138-153, January.
- Lynne G. Zucker & Michael R. Darby & Jeff S. Armstrong, 2003. "Commercializing knowledge: university science, knowledge capture and firm performance in biotechnology," Proceedings, Federal Reserve Bank of Dallas, issue Sep, pages 149-170.
- Lynne G. Zucker & Michael R. Darby & Jeff S. Armstrong, 2001. "Commercializing Knowledge: University Science, Knowledge Capture, and Firm Performance in Biotechnology," NBER Working Papers 8499, National Bureau of Economic Research, Inc.
- Stiglitz, Joseph E & Weiss, Andrew, 1981. "Credit Rationing in Markets with Imperfect Information," American Economic Review, American Economic Association, vol. 71(3), pages 393-410, June.
- Audretsch, David B & Stephan, Paula E, 1996. "Company-Scientist Locational Links: The Case of Biotechnology," American Economic Review, American Economic Association, vol. 86(3), pages 641-52, June.
- Jost, Peter-J, 1997. "Monitoring, Appeal, and Investigation: The Enforcement and Legal Process," Journal of Regulatory Economics, Springer, vol. 12(2), pages 127-46, September.
- Cetindamar, Dilek & Laage-Hellman, Jens, 2003. "Growth Dynamics in the Biomedical/Biotechnology System," Small Business Economics, Springer, vol. 20(4), pages 287-303, June.
- Fisher, Franklin M & Temin, Peter, 1973.
"Returns to Scale in Research and Development: What Does the Schumpeterian Hypothesis Imply ?,"
Journal of Political Economy,
University of Chicago Press, vol. 81(1), pages 56-70, Jan.-Feb..
- F. M. Fisher & P. Temin, 1971. "Returns-to-Scale in Research and Development: What Does the Schupeterian Hypothesis Imply?," Working papers 74, Massachusetts Institute of Technology (MIT), Department of Economics.
- Zucker, Lynne G. & Darby, Michael R. & Armstrong, Jeff, 1994. "Inter-Institutional Spillover Effects in the Commercialization of Bioscience," Institute for Social Science Research, Working Paper Series qt4d96f3xh, Institute for Social Science Research, UCLA.
- Mary K. Olson, 1997. "Firm Characteristics and the Speed of FDA Approval," Journal of Economics & Management Strategy, Wiley Blackwell, vol. 6(1), pages 377-401, 06.
- Murray, Fiona, 2004. "The role of academic inventors in entrepreneurial firms: sharing the laboratory life," Research Policy, Elsevier, vol. 33(4), pages 643-659, May.
When requesting a correction, please mention this item's handle: RePEc:eee:respol:v:38:y:2009:i:5:p:710-725. See general information about how to correct material in RePEc.
For technical questions regarding this item, or to correct its authors, title, abstract, bibliographic or download information, contact: (Zhang, Lei)
If references are entirely missing, you can add them using this form.